These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 24703772)

  • 1. Monocytic differentiation induced by side-chain modified analogs of vitamin D in ex vivo cells from patients with acute myeloid leukemia.
    Baurska H; Kiełbiński M; Biecek P; Haus O; Jaźwiec B; Kutner A; Marcinkowska E
    Leuk Res; 2014 May; 38(5):638-47. PubMed ID: 24703772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different susceptibilities to 1,25-dihydroxyvitamin D3-induced differentiation of AML cells carrying various mutations.
    Gocek E; Kiełbiński M; Baurska H; Haus O; Kutner A; Marcinkowska E
    Leuk Res; 2010 May; 34(5):649-57. PubMed ID: 19880182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Side-chain modified vitamin D analogs require activation of both PI 3-K and erk1,2 signal transduction pathways to induce differentiation of human promyelocytic leukemia cells.
    Marcinkowska E; Kutner A
    Acta Biochim Pol; 2002; 49(2):393-406. PubMed ID: 12362981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dimethyl fumarate and vitamin D derivatives cooperatively enhance VDR and Nrf2 signaling in differentiating AML cells in vitro and inhibit leukemia progression in a xenograft mouse model.
    Nachliely M; Trachtenberg A; Khalfin B; Nalbandyan K; Cohen-Lahav M; Yasuda K; Sakaki T; Kutner A; Danilenko M
    J Steroid Biochem Mol Biol; 2019 Apr; 188():8-16. PubMed ID: 30508646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype.
    Haferlach T; Bacher U; Alpermann T; Haferlach C; Kern W; Schnittger S
    Leuk Res; 2012 Jan; 36(1):51-8. PubMed ID: 21621842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prodifferentiation Activity of Novel Vitamin D₂ Analogs PRI-1916 and PRI-1917 and Their Combinations with a Plant Polyphenol in Acute Myeloid Leukemia Cells.
    Nachliely M; Sharony E; Bolla NR; Kutner A; Danilenko M
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27399677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-function analysis of vitamin D(2) analogs as potential inducers of leukemia differentiation and inhibitors of prostate cancer proliferation.
    Baurska H; Klopot A; Kielbinski M; Chrobak A; Wijas E; Kutner A; Marcinkowska E
    J Steroid Biochem Mol Biol; 2011 Aug; 126(1-2):46-54. PubMed ID: 21550403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The specific features of the immunophenotype of blast cells in patients with de novo normal karyotype acute myeloid leukemia and FLT3-ITD mutation].
    Gritsaev SV; Martynkevich IS; Chubukina ZhV; Petrova EV; Kostroma II; Ivanova MP; Martynenko LS; Potikhonova NA; Bubnova LN; Abdulkadyrov KM
    Ter Arkh; 2014; 86(3):71-7. PubMed ID: 24779074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of cup-like nuclei in blasts with FLT3 and NPM1 mutations in acute myeloid leukemia.
    Park BG; Chi HS; Jang S; Park CJ; Kim DY; Lee JH; Lee JH; Lee KH
    Ann Hematol; 2013 Apr; 92(4):451-7. PubMed ID: 23238897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination with a p38 MAPK inhibitor and an antioxidant.
    Wang Q; Harrison JS; Uskokovic M; Kutner A; Studzinski GP
    Leukemia; 2005 Oct; 19(10):1812-7. PubMed ID: 16107889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pan-caspase inhibitor Q-VD-OPh has anti-leukemia effects and can interact with vitamin D analogs to increase HPK1 signaling in AML cells.
    Chen-Deutsch X; Kutner A; Harrison JS; Studzinski GP
    Leuk Res; 2012 Jul; 36(7):884-8. PubMed ID: 22541691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation.
    Mori Y; Yoshimoto G; Kumano T; Miyamoto T; Iino T; Takenaka K; Iwasaki H; Harada N; Kinukawa N; Nagafuji K; Teshima T; Shimoda K; Akashi K; Harada M
    Eur J Haematol; 2007 Jul; 79(1):17-24. PubMed ID: 17598835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
    Bains A; Luthra R; Medeiros LJ; Zuo Z
    Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute myeloid leukemia: 2013 update on risk-stratification and management.
    Estey EH
    Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells.
    Koeffler HP; Hirji K; Itri L
    Cancer Treat Rep; 1985 Dec; 69(12):1399-407. PubMed ID: 2416438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The surface molecular signature of leukemic cells is associated with NPM1 mutations and FLT3 -ITD in patients with de novo acute myeloid leukemia.
    Su L; Gao SJ; Li W; Tan YH; Cui JW; Han W
    Acta Haematol; 2014; 131(3):148-52. PubMed ID: 24192815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cup-like acute myeloid leukemia: new disease or artificial phenomenon?
    Kroschinsky FP; Schäkel U; Fischer R; Mohr B; Oelschlaegel U; Repp R; Schaich M; Soucek S; Baretton G; Ehninger G; Thiede C;
    Haematologica; 2008 Feb; 93(2):283-6. PubMed ID: 18223289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation.
    Zhu HH; Liu YR; Jiang H; Lu J; Qin YZ; Jiang Q; Bao L; Ruan GR; Jiang B; Huang X
    Leuk Res; 2013 Jun; 37(6):624-30. PubMed ID: 23473998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of non-A-type NPM1 and FLT3 mutations in patients with normal karyotype acute myeloid leukemia.
    Park BG; Chi HS; Park SJ; Min SK; Jang S; Park CJ; Kim DY; Lee JH; Lee JH; Lee KH
    Acta Haematol; 2012; 127(2):63-71. PubMed ID: 22104247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.
    How J; Sykes J; Gupta V; Yee KW; Schimmer AD; Schuh AC; Minden MD; Kamel-Reid S; Brandwein JM
    Cancer; 2012 Dec; 118(24):6110-7. PubMed ID: 22736495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.